WO1999004810A3 - Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment - Google Patents
Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment Download PDFInfo
- Publication number
- WO1999004810A3 WO1999004810A3 PCT/EP1998/004621 EP9804621W WO9904810A3 WO 1999004810 A3 WO1999004810 A3 WO 1999004810A3 EP 9804621 W EP9804621 W EP 9804621W WO 9904810 A3 WO9904810 A3 WO 9904810A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mhc class
- lag
- adjuvant
- vaccination
- ligands
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 4
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000002671 adjuvant Substances 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000002255 vaccination Methods 0.000 title 1
- 102000043131 MHC class II family Human genes 0.000 abstract 3
- 108091054438 MHC class II family Proteins 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 102000017578 LAG3 Human genes 0.000 abstract 2
- 101150030213 Lag3 gene Proteins 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 230000000145 adjuvantlike effect Effects 0.000 abstract 1
- 238000002619 cancer immunotherapy Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98945090A EP1002108B1 (en) | 1997-07-25 | 1998-07-23 | Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment |
CA2293805A CA2293805C (en) | 1997-07-25 | 1998-07-23 | Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment |
UA2000020976A UA75322C2 (en) | 1997-07-25 | 1998-07-23 | Use of mhc class ii ligands as adjuvant for vaccination and lag-3 for cancer immunotherapy |
AU92547/98A AU753738B2 (en) | 1997-07-25 | 1998-07-23 | Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment |
BR9811037-3A BR9811037A (en) | 1997-07-25 | 1998-07-23 | Use of mhc class ii ligands as an adjuvant for vaccination and lag-3 in cancer treatment |
JP2000503862A JP4723722B2 (en) | 1997-07-25 | 1998-07-23 | Use of MHC class II ligands as vaccine adjuvants and use of LAG-3 in cancer therapy |
EA200000161A EA003740B1 (en) | 1997-07-25 | 1998-07-23 | Use of mhc class ii ligand, as a lag-3 or derivative, mutant form or soluble fragment lag-3, for preparation of immunotherapeutic medicament |
DE69834330T DE69834330T2 (en) | 1997-07-25 | 1998-07-23 | USE OF MHC CLASS II LIGANDS AS ADJUVANTIES FOR VACCINATION AND LAG-3 FOR CANCER THERAPY |
IL13421298A IL134212A0 (en) | 1997-07-25 | 1998-07-23 | Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment |
KR1020007000265A KR100603075B1 (en) | 1997-07-25 | 1998-07-23 | Use of mhc class ? ligands as adjuvant for vaccination and of lag-3 in cancer treatment |
EEP200000039A EE200000039A (en) | 1997-07-25 | 1998-07-23 | Use of MHC Class II Ligand, Pharmaceutical Composition, Transfected Tumor Cells, Method of Preparing Transfected Cells and Tumor Cells, and Their Use |
IL134212A IL134212A (en) | 1997-07-25 | 2000-01-24 | Use of lag-3 as an mhc class ii ligand in combination with an antigen for the manufacture of a medicament for amplifying a cell response to an antigen |
NO20000378A NO20000378D0 (en) | 1997-07-25 | 2000-01-25 | Use of MHC class II ligands as adjuvants for vaccination and LAG-3 in cancer treatment |
US09/492,113 US6410509B1 (en) | 1997-07-25 | 2000-01-27 | Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment |
HK01100662A HK1030014A1 (en) | 1997-07-25 | 2001-01-30 | Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment. |
US10/041,600 US7109026B2 (en) | 1997-07-25 | 2002-01-10 | Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97401800.4 | 1997-07-25 | ||
EP97401800A EP0893507A1 (en) | 1997-07-25 | 1997-07-25 | Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/492,113 Continuation US6410509B1 (en) | 1997-07-25 | 2000-01-27 | Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999004810A2 WO1999004810A2 (en) | 1999-02-04 |
WO1999004810A3 true WO1999004810A3 (en) | 1999-07-08 |
Family
ID=8229825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1998/004621 WO1999004810A2 (en) | 1997-07-25 | 1998-07-23 | Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment |
Country Status (20)
Country | Link |
---|---|
US (2) | US6410509B1 (en) |
EP (3) | EP0893507A1 (en) |
JP (1) | JP4723722B2 (en) |
KR (1) | KR100603075B1 (en) |
CN (1) | CN1184320C (en) |
AT (2) | ATE478956T1 (en) |
AU (1) | AU753738B2 (en) |
BR (1) | BR9811037A (en) |
CA (2) | CA2293805C (en) |
DE (2) | DE69841866D1 (en) |
DK (1) | DK1002108T3 (en) |
EA (3) | EA003740B1 (en) |
EE (1) | EE200000039A (en) |
ES (1) | ES2262242T3 (en) |
HK (1) | HK1030014A1 (en) |
IL (2) | IL134212A0 (en) |
NO (1) | NO20000378D0 (en) |
PT (1) | PT1002108E (en) |
UA (1) | UA75322C2 (en) |
WO (1) | WO1999004810A2 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1295895B1 (en) * | 2001-09-19 | 2011-08-10 | Institut Gustave Roussy | Peptides and proteins binding to glu-pro motifs, therapeutical compositions containing the same and applications thereof |
WO2004078928A2 (en) * | 2003-02-28 | 2004-09-16 | The Johns Hopkins University | T cell regulation |
KR20050082389A (en) * | 2004-02-18 | 2005-08-23 | 메덱스젠 주식회사 | Pharmaceutical composition for treatment of transplantation rejection comprising concatameric immunoadhesin |
FR2868781B1 (en) * | 2004-04-13 | 2008-02-22 | Immutep | VACCINE COMPOSITION COMPRISING ANTIGEN-COUPLED CLAY II MHC LIGAND, METHOD OF PREPARATION AND USES |
EP2044949A1 (en) * | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
WO2011031139A1 (en) | 2009-09-09 | 2011-03-17 | Universiteit Utrecht Holding B.V. | An ataq protein or a part thereof as a vaccine |
SA110310855B1 (en) | 2009-11-13 | 2014-09-16 | Laboratories Leti S L Unipersonal | The Use of an l3 and/or l5 Source as a Vaccine or as a Diagnostic for a Parasitic Disease |
US9187751B2 (en) | 2010-11-10 | 2015-11-17 | Laboratorios Leti, S.L. | Adjuvant |
GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
JOP20200094A1 (en) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-1 and uses thereof |
CN103751778B (en) * | 2014-01-28 | 2016-09-28 | 复旦大学 | Cordycepin application in the immunological adjuvant preparing broad-spectrum vaccine potentiation |
TWI777174B (en) | 2014-03-14 | 2022-09-11 | 瑞士商諾華公司 | Antibody molecules to lag-3 and uses thereof |
BR112017006969A2 (en) | 2014-10-07 | 2017-12-19 | Cytlimic Inc | hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using the same, immunity inducer and antigen presenting cell production method |
US9827308B2 (en) | 2014-12-10 | 2017-11-28 | Wisconsin Alumni Research Foundation | Mini-intronic plasmid DNA vaccines in combination with LAG3 blockade |
GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
CN107428815B (en) | 2015-03-09 | 2021-07-09 | Cytlimic公司 | GPC 3-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immune inducer, and method for producing antigen-presenting cell |
ES2844049T3 (en) * | 2015-04-07 | 2021-07-21 | Cytlimic Inc | Cancer vaccine adjuvant |
SG10201912485PA (en) | 2015-05-13 | 2020-02-27 | Agenus Inc | Vaccines for treatment and prevention of cancer |
EP3943098A3 (en) | 2015-07-16 | 2022-05-11 | Biokine Therapeutics Ltd. | Compositions and methods for treating cancer |
US10265379B2 (en) | 2015-09-16 | 2019-04-23 | Annabelle Rodriguez Oquendo | Use of recombinant lymphocyte activation gene-3 as a companion therapeutic for patients at risk for cardiovascular disease and other chronic inflammatory diseases |
EP3349790A1 (en) | 2015-09-18 | 2018-07-25 | Rijksuniversiteit Groningen | Long chain inulin for stimulating an immune response |
RU2759728C2 (en) * | 2016-10-11 | 2021-11-17 | Ситлимик Инк. | Medicinal product |
CN108204958A (en) * | 2016-12-19 | 2018-06-26 | 伊缪泰普有限公司 | binding assay |
CA3096909A1 (en) | 2018-04-26 | 2019-10-31 | Agenus Inc. | Heat shock protein-binding peptide compositions and methods of use thereof |
KR20210090618A (en) * | 2018-09-27 | 2021-07-20 | 제노세아 바이오사이언스, 인코퍼레이티드 | treatment method |
JP2020138940A (en) | 2019-02-28 | 2020-09-03 | テルモ株式会社 | Therapeutic method |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989002922A1 (en) * | 1987-10-02 | 1989-04-06 | Genentech, Inc. | Adheson variants |
WO1990001870A1 (en) * | 1988-08-22 | 1990-03-08 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Retroviral vectors expressing soluble cd4; a gene therapy for aids |
EP0385909A2 (en) * | 1989-03-03 | 1990-09-05 | MicroGeneSys, Inc. | A kit or composition for the prevention or treatment of HIV-1 infections |
EP0394827A1 (en) * | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
WO1991010682A1 (en) * | 1990-01-08 | 1991-07-25 | Institut National De La Sante Et De La Recherche Medicale | Proteins produced by human lymphocytes, dna sequence coding these proteins, and pharmaceutical and biological uses thereof |
WO1995021528A1 (en) * | 1994-02-14 | 1995-08-17 | The General Hospital Corporation | Targeted cytolysis of hiv-infected cells by chimeric cd4 receptor-bearing cells |
WO1995030750A2 (en) * | 1994-05-06 | 1995-11-16 | Institut Gustave Roussy | Lag-3 protein soluble polypeptide fractions, method of production, therapeutic composition and anti-idiotype antibody |
WO1996004386A1 (en) * | 1994-08-05 | 1996-02-15 | Warner-Lambert Company | Method of using transdominant negative retroviral integrase in the treatment of retroviral infection |
WO1996017874A1 (en) * | 1994-12-07 | 1996-06-13 | F. Hoffmann-La Roche Ag | Monoclonal antibody fragments having immunosuppressant activity |
WO1996020215A2 (en) * | 1994-12-23 | 1996-07-04 | Laboratoires Om S.A. | Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases |
WO1997024132A1 (en) * | 1995-12-28 | 1997-07-10 | The Johns Hopkins University School Of Medicine | Allogeneic paracrine cytokine tumor vaccines |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02231083A (en) * | 1988-08-31 | 1990-09-13 | Eisai Co Ltd | Recombinant natural killer cell-activating factor |
AU675702B2 (en) * | 1993-01-26 | 1997-02-13 | Leslie R. Coney | Compositions and methods for delivery of genetic material |
SE510135C2 (en) * | 1994-05-05 | 1999-04-19 | Berol Nobel Ab | Aqueous suspension of a cellulose ether, methods for its preparation and composition |
-
1997
- 1997-07-25 EP EP97401800A patent/EP0893507A1/en not_active Withdrawn
-
1998
- 1998-07-23 AU AU92547/98A patent/AU753738B2/en not_active Expired
- 1998-07-23 EP EP98945090A patent/EP1002108B1/en not_active Expired - Lifetime
- 1998-07-23 EE EEP200000039A patent/EE200000039A/en unknown
- 1998-07-23 CA CA2293805A patent/CA2293805C/en not_active Expired - Lifetime
- 1998-07-23 EA EA200000161A patent/EA003740B1/en not_active IP Right Cessation
- 1998-07-23 UA UA2000020976A patent/UA75322C2/en unknown
- 1998-07-23 WO PCT/EP1998/004621 patent/WO1999004810A2/en active IP Right Grant
- 1998-07-23 EP EP06008545A patent/EP1698701B1/en not_active Expired - Lifetime
- 1998-07-23 CA CA2732570A patent/CA2732570C/en not_active Expired - Lifetime
- 1998-07-23 KR KR1020007000265A patent/KR100603075B1/en not_active IP Right Cessation
- 1998-07-23 AT AT06008545T patent/ATE478956T1/en not_active IP Right Cessation
- 1998-07-23 ES ES98945090T patent/ES2262242T3/en not_active Expired - Lifetime
- 1998-07-23 DE DE69841866T patent/DE69841866D1/en not_active Expired - Lifetime
- 1998-07-23 DE DE69834330T patent/DE69834330T2/en not_active Expired - Lifetime
- 1998-07-23 AT AT98945090T patent/ATE324455T1/en active
- 1998-07-23 EA EA200300092A patent/EA200300092A1/en unknown
- 1998-07-23 DK DK98945090T patent/DK1002108T3/en active
- 1998-07-23 JP JP2000503862A patent/JP4723722B2/en not_active Expired - Lifetime
- 1998-07-23 IL IL13421298A patent/IL134212A0/en unknown
- 1998-07-23 EA EA200200565A patent/EA005405B1/en not_active IP Right Cessation
- 1998-07-23 PT PT98945090T patent/PT1002108E/en unknown
- 1998-07-23 BR BR9811037-3A patent/BR9811037A/en not_active IP Right Cessation
- 1998-07-23 CN CNB988075474A patent/CN1184320C/en not_active Expired - Lifetime
-
2000
- 2000-01-24 IL IL134212A patent/IL134212A/en not_active IP Right Cessation
- 2000-01-25 NO NO20000378A patent/NO20000378D0/en not_active Application Discontinuation
- 2000-01-27 US US09/492,113 patent/US6410509B1/en not_active Expired - Lifetime
-
2001
- 2001-01-30 HK HK01100662A patent/HK1030014A1/en not_active IP Right Cessation
-
2002
- 2002-01-10 US US10/041,600 patent/US7109026B2/en not_active Expired - Fee Related
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989002922A1 (en) * | 1987-10-02 | 1989-04-06 | Genentech, Inc. | Adheson variants |
WO1990001870A1 (en) * | 1988-08-22 | 1990-03-08 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Retroviral vectors expressing soluble cd4; a gene therapy for aids |
EP0385909A2 (en) * | 1989-03-03 | 1990-09-05 | MicroGeneSys, Inc. | A kit or composition for the prevention or treatment of HIV-1 infections |
EP0394827A1 (en) * | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
WO1991010682A1 (en) * | 1990-01-08 | 1991-07-25 | Institut National De La Sante Et De La Recherche Medicale | Proteins produced by human lymphocytes, dna sequence coding these proteins, and pharmaceutical and biological uses thereof |
WO1995021528A1 (en) * | 1994-02-14 | 1995-08-17 | The General Hospital Corporation | Targeted cytolysis of hiv-infected cells by chimeric cd4 receptor-bearing cells |
WO1995030750A2 (en) * | 1994-05-06 | 1995-11-16 | Institut Gustave Roussy | Lag-3 protein soluble polypeptide fractions, method of production, therapeutic composition and anti-idiotype antibody |
WO1996004386A1 (en) * | 1994-08-05 | 1996-02-15 | Warner-Lambert Company | Method of using transdominant negative retroviral integrase in the treatment of retroviral infection |
WO1996017874A1 (en) * | 1994-12-07 | 1996-06-13 | F. Hoffmann-La Roche Ag | Monoclonal antibody fragments having immunosuppressant activity |
WO1996020215A2 (en) * | 1994-12-23 | 1996-07-04 | Laboratoires Om S.A. | Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases |
WO1997024132A1 (en) * | 1995-12-28 | 1997-07-10 | The Johns Hopkins University School Of Medicine | Allogeneic paracrine cytokine tumor vaccines |
Non-Patent Citations (7)
Title |
---|
BAIXERAS E ET AL: "CHARACTERIZATION OF THE LYMPHOCYTE ACTIVATION GENE 3-ENCODED PROTEIN. A NEW LIGAND FOR HUMAN LEUKOCYTE ANTIGEN CLASS II ANTIGENS", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 176, August 1992 (1992-08-01), pages 327 - 337, XP000677772 * |
DRANOFF ET AL.: "Prospects for the immunotherapy of cancer using genetically modified tumour cells", KLINISCHE PHARMAKOLOGIE, vol. 9, September 1992 (1992-09-01), pages 22 - 29, XP002058638 * |
HUARD ET AL.: "Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand", IMMUNOGENETICS, vol. 39, 1994, pages 213-217, XP002058640 * |
HUARD ET AL.: "T cell major histocompatibility complex class II molecules downregulate CD4+ T cell clone responses following LAG-3 binding", EUR. J. IMMUNOLOG., vol. 26, 1996, pages 1180 - 1186, XP000672293 * |
HUARD ET AL.: "T cell MHC class II molecules downregulate T cell proliferation following LAG-3 binding", 9TH INTERNATIONAL CONGRESS OF IMMUNOLOGY: SAN FRANCISCO, CALIFORNIA, USA, XP002050654 * |
WAHREN B: "Gene vaccines", IMMUNOTECHNOLOGY, vol. 2, no. 2, June 1996 (1996-06-01), pages 77-83, XP004052672 * |
WILLIAMS ET AL.: "Genetic infection induces protective in vivo immune responses", DNA AND CELL BIOLOGY, vol. 12, no. 8, 1993, pages 675-683, XP002058639 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999004810A3 (en) | Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment | |
ID21529A (en) | METHODS AND COMPOSITIONS FOR TUMOR TREATMENT, PREVENTION, RELATIONSHIP RELATED TO TUMORS AND COCOEX | |
ATE106013T1 (en) | GLUCAN AND ADJUVANT DRUG DELIVERY SYSTEM. | |
HU9602937D0 (en) | Compositions comprising dna damaging agents and p53 | |
EP2022800A3 (en) | Compositions for the therapy and diagnosis of ovarian cancer | |
WO2000062800A3 (en) | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide | |
IL125590A (en) | Peptide immunogens, process for their preparation and use thereof as vaccines against allergies | |
IL134345A0 (en) | Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon | |
IL112969A0 (en) | Pharmaceutical composition comprising t-cell actiVator for the treatment of cancer | |
IL126803A (en) | Method and composition for reconforming multiepitopic antigens to initiate an immune response | |
AU7242796A (en) | Leishmania antigens for use in the therapy and diagnosis of leishmaniasis | |
DE69637571D1 (en) | COMPOSITION AND METHOD FOR REINFORCING THE IMMUNE RESPONSE OF ANTIGEN-PRESENTING CELLS | |
EP0661061A3 (en) | Vaccine composition for eliciting an immune response against N-glycolylated gangliosides and its use for cancer treatment. | |
HUP0100350A3 (en) | Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use | |
EP1820514A3 (en) | Therapeutic compositions that produce an immune response by altering the antigen | |
WO1998035045A3 (en) | Leishmania antigens for use in the therapy and diagnosis of leishmaniasis | |
WO2000078800A3 (en) | Combined decorin binding protein and outer surface protein compositions and methods of use | |
WO1997033620A3 (en) | Compounds for treating tumours | |
BR0212446A (en) | Use of 4-pyridylmethylphthalazine for cancer treatment | |
MY127452A (en) | Vaccines. | |
NZ501641A (en) | Ganglioside immunostimulating complexes and their use in treating cancer | |
WO2003020306A1 (en) | Desensitizers | |
NZ511034A (en) | Methods of downmodulating the immune response to therapeutic proteins | |
DE59712247D1 (en) | MAMMA CARCINOMA ASSOCIATED GEN | |
EP1422238A3 (en) | Leishmania antigens for use in the therapy and diagnosis of leishmaniasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 134212 Country of ref document: IL Ref document number: 98807547.4 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref document number: 2293805 Country of ref document: CA Ref document number: 2293805 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/012024 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 92547/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007000265 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998945090 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09492113 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200000161 Country of ref document: EA |
|
WWP | Wipo information: published in national office |
Ref document number: 1998945090 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007000265 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 92547/98 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020007000265 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998945090 Country of ref document: EP |